Table: q1_q4_2023_prescription_drugs_intro_to_market , manufacturer_name like X*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	drug_category	drug_category_source	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
XGen Pharmaceuticals DJB	39822303002	Pentamidine for Inhalation 300mg/vial	Generic	FDA	2023-07-01	90.0000	None	1	7800	None	None	None	None	None	None	The marketing date for this item has been updated with a marketing launch date of 6/30/2023 in the CMS date bank (and other databanks as needed).	None
XGen Pharmaceuticals DJB	39822305002	Pentamidine for Injection 300mg/vial x10	Generic	FDA	2023-07-01	900.0000	None	1	5364	None	None	None	None	None	None	The marketing date for this item has been updated with a marketing launch date of 6/30/2023 in the CMS date bank (and other databanks as needed).	None